Beta Bionics (NASDAQ:BBNX – Get Free Report) and AngioDynamics (NASDAQ:ANGO – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.
Profitability
This table compares Beta Bionics and AngioDynamics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beta Bionics | -61.31% | -26.30% | -23.25% |
| AngioDynamics | -10.12% | -4.49% | -2.96% |
Earnings & Valuation
This table compares Beta Bionics and AngioDynamics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beta Bionics | $100.25 million | 8.60 | -$73.20 million | ($1.65) | -11.61 |
| AngioDynamics | $320.17 million | 1.62 | -$36.74 million | ($0.78) | -15.85 |
AngioDynamics has higher revenue and earnings than Beta Bionics. AngioDynamics is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Beta Bionics has a beta of 3.39, meaning that its share price is 239% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for Beta Bionics and AngioDynamics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beta Bionics | 1 | 4 | 9 | 1 | 2.67 |
| AngioDynamics | 1 | 1 | 2 | 1 | 2.60 |
Beta Bionics currently has a consensus target price of $24.00, suggesting a potential upside of 25.26%. AngioDynamics has a consensus target price of $19.00, suggesting a potential upside of 53.72%. Given AngioDynamics’ higher probable upside, analysts plainly believe AngioDynamics is more favorable than Beta Bionics.
Insider & Institutional Ownership
89.4% of AngioDynamics shares are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 6.0% of AngioDynamics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
AngioDynamics beats Beta Bionics on 9 of the 14 factors compared between the two stocks.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
About AngioDynamics
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
